Literature DB >> 24292992

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis.

Lu Tian1, Lihui Zhao, L J Wei.   

Abstract

For designing, monitoring, and analyzing a longitudinal study with an event time as the outcome variable, the restricted mean event time (RMET) is an easily interpretable, clinically meaningful summary of the survival function in the presence of censoring. The RMET is the average of all potential event times measured up to a time point τ and can be estimated consistently by the area under the Kaplan-Meier curve over $[0, \tau ]$. In this paper, we study a class of regression models, which directly relates the RMET to its "baseline" covariates for predicting the future subjects' RMETs. Since the standard Cox and the accelerated failure time models can also be used for estimating such RMETs, we utilize a cross-validation procedure to select the "best" among all the working models considered in the model building and evaluation process. Lastly, we draw inferences for the predicted RMETs to assess the performance of the final selected model using an independent data set or a "hold-out" sample from the original data set. All the proposals are illustrated with the data from the an HIV clinical trial conducted by the AIDS Clinical Trials Group and the primary biliary cirrhosis study conducted by the Mayo Clinic.

Entities:  

Keywords:  Accelerated failure time model; Cox model; Cross-validation; Hold-out sample; Personalized medicine; Perturbation-resampling method

Mesh:

Year:  2013        PMID: 24292992      PMCID: PMC3944973          DOI: 10.1093/biostatistics/kxt050

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  9 in total

1.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Efficient estimation of the distribution of quality-adjusted survival time.

Authors:  H Zhao; A A Tsiatis
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

3.  Simultaneous inferences on the contrast of two hazard functions with censored observations.

Authors:  Peter B Gilbert; L J Wei; Michael R Kosorok; John D Clemens
Journal:  Biometrics       Date:  2002-12       Impact factor: 2.571

4.  Distribution-free inference on contrasts of arbitrary summary measures of survival.

Authors:  Kyle D Rudser; Michael L LeBlanc; Scott S Emerson
Journal:  Stat Med       Date:  2012-02-23       Impact factor: 2.373

5.  Regression analysis of restricted mean survival time based on pseudo-observations.

Authors:  Per Kragh Andersen; Mette Gerster Hansen; John P Klein
Journal:  Lifetime Data Anal       Date:  2004-12       Impact factor: 1.588

6.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

7.  Calibrating parametric subject-specific risk estimation.

Authors:  T Cai; L Tian; Hajime Uno; Scott D Solomon; L J Wei
Journal:  Biometrika       Date:  2010-06       Impact factor: 2.445

8.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

9.  Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.

Authors:  Lihui Zhao; Lu Tian; Hajime Uno; Scott D Solomon; Marc A Pfeffer; Jerald S Schindler; Lee Jen Wei
Journal:  Clin Trials       Date:  2012-08-22       Impact factor: 2.486

  9 in total
  43 in total

1.  The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.

Authors:  Gaohong Dong; Lu Mao; Bo Huang; Margaret Gamalo-Siebers; Jiuzhou Wang; GuangLei Yu; David C Hoaglin
Journal:  J Biopharm Stat       Date:  2020-06-17       Impact factor: 1.051

2.  Evaluating surrogate marker information using censored data.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Stat Med       Date:  2017-01-15       Impact factor: 2.373

3.  Analysis of multiple diverse phenotypes via semiparametric canonical correlation analysis.

Authors:  Denis Agniel; Tianxi Cai
Journal:  Biometrics       Date:  2017-04-13       Impact factor: 2.571

4.  Patient subgroup identification for clinical drug development.

Authors:  Xin Huang; Yan Sun; Paul Trow; Saptarshi Chatterjee; Arunava Chakravartty; Lu Tian; Viswanath Devanarayan
Journal:  Stat Med       Date:  2017-02-01       Impact factor: 2.373

5.  Tree based weighted learning for estimating individualized treatment rules with censored data.

Authors:  Yifan Cui; Ruoqing Zhu; Michael Kosorok
Journal:  Electron J Stat       Date:  2017-10-18       Impact factor: 1.125

6.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

7.  Adjusted restricted mean survival times in observational studies.

Authors:  Sarah C Conner; Lisa M Sullivan; Emelia J Benjamin; Michael P LaValley; Sandro Galea; Ludovic Trinquart
Journal:  Stat Med       Date:  2019-05-22       Impact factor: 2.373

8.  Optimal stratification in outcome prediction using baseline information.

Authors:  Florence H Yong; Lu Tian; Sheng Yu; Tianxi Cai; L J Wei
Journal:  Biometrika       Date:  2016-12-08       Impact factor: 2.445

9.  Veridical Causal Inference using Propensity Score Methods for Comparative Effectiveness Research with Medical Claims.

Authors:  Ryan D Ross; Xu Shi; Megan E V Caram; Pheobe A Tsao; Paul Lin; Amy Bohnert; Min Zhang; Bhramar Mukherjee
Journal:  Health Serv Outcomes Res Methodol       Date:  2020-10-20

10.  Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Authors:  Lu Tian; Haoda Fu; Stephen J Ruberg; Hajime Uno; Lee-Jen Wei
Journal:  Biometrics       Date:  2017-09-12       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.